Media & Press Updates

exoprother_socal_lab_investors_event1.png

In lab Investors event

Investors event in our R&D Lab at Colab square Yokneam, taking a glimpse into the digital microscope along with markers on milestones achieved.

July 9th, 2021

LanaAndAlexAtColab.jpeg

New R&D lab at Colab Square Facility, Yokneam

Beginning May 2021, ExoProTher is operating a new R&D lab situated at unique Colab Square facility in Yokneam Industrial park. ExoProTher is joining a line of exciting and promising biotech companies.

The combination of location, equipment and environment allow to boost R&D activities and attract top talent to the expanding team.

June 24, 2021

scs_exoprother_small.png

2021 Virtual World Stem Cell Summit

ExoProTher Medical - Co-founder & CEO Dr. Lana Volokh
at The Investor Forum - at the 2021 Virtual World Stem Cell Summit. (hosted by channelchek)

June 17th, 2021

r_ISEV2021_1.png

SEV2021 Annual Meeting

ExoProTher's scientific abstract reporting our recent preclinical results at the Annual Meeting of International Society for Extracellular Vesicles.

May 18-21, 2021

r_Magische kugel against cancer abstract

Magische kugel against cancer

"Magic bullet against cancer"

Short Communication - Journal of Molecular Oncology Research (2021) Volume 5, Issue 2

March 10th, 2021

ExoProTher Globes.png

New media coverage - Globes article featuring ExoProTher

ExoProTher article in Israeli business daily the "Globes".
 

Hebrew article by Globes' biomed reporter, Gali Weinreb.

January 6th, 2021

r_finalist.png

Startup World Cup

ExoProTher is honored to be selected among top ten Israeli companies in the largest startup competition in the world - Startup World Cup.

 

Best regards,

Lana Volokh - CEO

January 5th, 2021

r_milestone_road_last.jpg

ExoProTher milestone achieved

I am pleased to share with our followers and investors the latest in vivo results.

Two weeks ago, a successful in vivo experiment on mouse model of colon cancer ended with impressive results. Life span of treated mice was significantly prolonged after single dose of Exo, while 25% of them remained tumor-free after the experiment completion. Additional in vivo studies using other cancer models are in progress.

 

Best regards,

Lana Volokh - CEO

November 12, 2020

r_ExoProTher new recruites.jpg

New recruits & Additional facility

Exciting growth period for ExoProTher Medical: we opened a new laboratory facility and brought on board new talent.

 

The new laboratory started functioning in Shlomi, Israel. It will focus on optimizing production and characterization of EXO_ compounds. 

 

With extended R&D team, we continue to broaden and deepen our research capabilities.

September 13, 2020

r_SoCal super position.jpg

SoCal
Startup Day

Velocity on the rise not only in our labs.

Great boost coming from amazing crowd engagement in the SoCal startup event.

February 26, 2020

r_SoCal_Publication.jpg

SoCal
Startup Day

We are excited to attend the SoCal Startup Day and present our development.
Come see our quick-fire presentation as part of the start-up competition and visit us at booth #22 to learn more about our unique approach.

February 26, 2020

r_Interview - Tel-Aviv stock exchange.jp

@Tel-Aviv stock exchange

ExitValley and Eternity Capital investors event at the Tel-Aviv stock exchange.

February 5, 2020

r_shaypic_callforaction.jpg

Call for Action

ExoProTher VP Business Development update and call for action.


December 12, 2019

r_exitValley.jpg

ExitValley's campaign

About a week into the campaign and the traction is high,

More than 100% of initial funding target. 

December 9, 2019 

Alex_Tandler_ExoProTher_ExitValley_01.jp

ExitValley's Investors meeting

What a great event to be part of – first ExitValley’s Investors meeting!

Dr. Alex Tendler, co-founder and CTO of ExoProTher Medical, presented our unique concept and its outstanding potential to the very interested audience.

Excellent traction, 

ExoProTher Medical launched the crowdfunding campaign using ExitValley platform.
 

It is super cool to see first investment after less than 12 hours. Amazing start.

December 2, 2019

r_oncoTalk.jpg

TheMarker's OncoTalk 
publication